Share on StockTwits

IDEXX Laboratories (NASDAQ:IDXX) Director M Anne Szostak purchased 2,000 shares of the stock in a transaction dated Wednesday, August 13th. The shares were purchased at an average price of $127.03 per share, for a total transaction of $254,060.00. Following the completion of the transaction, the director now directly owns 7,000 shares in the company, valued at approximately $889,210. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of IDEXX Laboratories (NASDAQ:IDXX) opened at 126.34 on Monday. IDEXX Laboratories has a 52-week low of $92.09 and a 52-week high of $140.00. The stock’s 50-day moving average is $130.4 and its 200-day moving average is $126.4. The company has a market cap of $6.351 billion and a price-to-earnings ratio of 34.73.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Friday, July 25th. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.05. The company had revenue of $390.00 million for the quarter, compared to the consensus estimate of $385.20 million. During the same quarter in the previous year, the company posted $0.99 earnings per share. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts predict that IDEXX Laboratories will post $3.85 earnings per share for the current fiscal year.

A number of research firms have recently commented on IDXX. Analysts at Piper Jaffray raised their price target on shares of IDEXX Laboratories from $125.00 to $126.00 in a research note on Monday, July 28th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of IDEXX Laboratories in a research note on Wednesday, July 16th. They now have a $139.00 price target on the stock. Finally, analysts at Canaccord Genuity upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, June 24th. They now have a $148.00 price target on the stock, up previously from $116.00. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. IDEXX Laboratories has a consensus rating of “Hold” and an average target price of $136.60.

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets.

Receive News & Ratings for IDEXX Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.